EATG » TB CAB’s proposed development pathway for regimens to treat XDR-TB

TB CAB’s proposed development pathway for regimens to treat XDR-TB

One of the most critical scientific questions in TB today is the optimal combination of new and repurposed drugs for the treatment of extensively drug-resistant, pre- extensively drug-resistant, and hard-to-treat multidrug-resistant TB (XDR-TB, pre-XDR-TB, MDR-TB).

Тhe Global TB Community Advisory Board (TB CAB) has developed a position paper regarding the optimal design for future evaluation of regimens for the treatment of XDR-TB in order to influence the direction of discussions ongoing among stakeholders in the TB field.

The position paper can be downloaded here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
TB Online
News categories: Tuberculosis